USP Names “Key” Drug Types, But Leaves Them Out Of Formulary Guidelines

The U.S. Pharmacopeia is dropping recommended drug class subdivisions from its model guidelines in favor of providing CMS with a list of "formulary key drug types" the agency should consider in reviewing plans for the Medicare Rx program